Amniotic Membrane Market size was valued at USD 2.1 billion in 2024 and is anticipated to surpass USD 5.3 billion by 2037, registering a CAGR of 8.1% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of amniotic membrane is evaluated at USD 2.2 billion.
The market is bolstering due to its unique characteristics, as it is rich in cytokines and collagen which is used to accelerate wound healing, and tissue regeneration, and reduce inflammation. Moreover, an increased incidence of chronic diseases and wounds, tissue engineering advancement, and growing demand for minimally invasive procedures stimulate market growth. For instance, in October 2024, The Primary Care Dermatology Society statistics revealed, that over 500,000 people in the UK are now living with some form of venous ulceration, double the cases recorded a decade ago. The surge in cases has put an unprecedented demand on advanced wound care solutions such as amniotic membrane products.
Moreover, companies and industries are entering into strategic collaborations to discover new methodologies and procedures to aid in surgical procedures. For instance, in July 2023, Celularity Inc. and Verséa Ophthalmics, LLC announced that the companies entered into an exclusive U.S. commercialization agreement. Under this agreement, Verséa Ophthalmics distributes Celularity's BIOVANCE(R) and BIOVANCE(R) 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.
In addition, amniotic membrane is proven to be effective in treating eyesight-related concerns. For instance, in June 2024, a study published in Graefe's Archive for Clinical and Experimental Ophthalmology tested the vacuum-dehydrated amniotic membrane, Omnigen, on a contact lens, Omnilenz, in the treatment of acute chemical eye injuries. In 23 eyes, there was approximately 50% marked epithelial healing with improvement of visual acuity at the first application. Omnilenz was tolerated very well, with no serious complications, so it is effective for chemical eye injuries.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.1% |
|
Base Year Market Size (2024) |
USD 2.1 billion |
|
Forecast Year Market Size (2037) |
USD 5.3 billion |
|
Regional Scope |
|
Product (Cryopreserved, Lyophilized)
In amniotic membrane market, cryopreserved segment is set to reach USD 52.8 billion by 2037. These membranes are used to a great extent in the treatment and management of surgical wounds and incisions. For instance, in January 2021, Organogensis, Inc. released ReNu, a cryopreserved amniotic suspension allograft for the treatment of symptomatic knee osteoarthritis. Owing to their properties which include maintaining a waterproof seal, reducing inflammatory responses, and preventing the transmission of disease, the market is gaining significance. Hence, the market is experiencing a robust growth.
End use (Hospitals, Ambulatory Surgical Centers, Speciality Clinics, Research and Academic Institutes, Other end users)
Based on end use, the hospital segment is expected to garner the major share in the amniotic membrane market by the end of 2037. The rapid expansion of healthcare infrastructure provides better access to advanced treatments. For instance, in February 2024, Verséa launched a point-of-care platform for amniotic membrane grafting. This innovation helps quickly test and thus accelerate testing effectively, improving patient care in ophthalmology with rapid diagnostic results and possible treatments. Furthermore, the membranes have a regenerative property, an anti-inflammatory effect, and a scarring reduction factor. Therefore, hospitals render efficacy in the treatment of chronic wounds, corneal defects, and reconstructive surgeries.
Our in-depth analysis of the global amniotic membrane market includes the following segments:
|
Product |
|
|
Application |
|
|
End use |
|
North America Market Statistics
By 2037, North America amniotic membrane market is set to capture over 62.2% revenue share. The growing awareness in the last few years has increased the number of transplants, and therefore, the demand for these tissue-based solutions is increasing. This awareness has also grown in several donations, and hence, the market revenue is growing. An increase in R&D activities for expanding the efficacy of amniotic membranes as well as developing new products will help in growing this market.
The U.S. amniotic membrane market will witness exponential growth attributable to the collaborations and increasing commercialization of amniotic membranes in vast applications. For instance, in September 2023, NovaBay Pharmaceuticals launched the Avenova Allograft in the U.S. through its physician-dispensed channel. Furthermore, the two companies announced an agreement in July 2024, wherein the right to commercialize Amniotic Tissue Allograft by BioStem Technologies was granted to NovaBay under the brand Avenova. The Avenova allograft will be available in the global market of ophthalmology amniotic membranes.
Canada amniotic membrane market is evolving at a steady pace, owing to the growing concern over anti-aging and skin-related issues. In recent years, the population in the country has embraced many ophthalmology and cosmetic surgical treatments. In addition, increased numbers of healthcare professionals are acknowledging amniotic membrane, particularly its healing aspects, for widespread utilization in treating surgical wounds. Hence, the demand for minimally invasive surgical techniques has led to the use of amniotic membranes in the country.
Asia Pacific Market Analysis
The Asia Pacific amniotic membrane market is growing rapidly. Advances in technology witnesses the improvement of processing techniques and storage methods within the industry. This would contribute to amniotic membrane-based products becoming even more credible and reliable, a trend likely to boost global demand for amniotic membranes highly in the long run. In addition, increasing skin care treatments is the most popular trend as amniotic tissues aid in the healing of wounds and burns.
China is expected to grow over the forecast period. The "Healthy China 2030 Strategy" has been in recent years an emphasis on health in China, and further amplified by the COVID-19 pandemic in 2020. The expansion of healthcare infrastructure, increased healthcare workforce, and strong medical facilities in China will drive market growth in the future. For example, as per CEIC data, in 2022, the number of hospitals in China rose to 36,976 units from 36,570 units reported in 2021. Hence, increasing the opportunities for the amniotic membrane market to flourish.
The India amniotic membrane market is predicted to grow significantly as the amniotic dry eye therapy increases. Amniotic membranes are frequently employed as a biological bandage during eye procedures to heal or replace damaged eye tissues in the country. It was revealed in the statistics by the National Blindness & Visual Impairment Survey India that cataract was the principal cause of blindness (66.2%), severe visual impairment (80.7%), and moderate visual impairment (70.2%) amongst the population. Thus, driving demand for the amniotic membrane-oriented solution for eye treatment.
Companies are catalysts in shaping the landscape of the amniotic membrane market. Their continuous effort and research to innovate the usage of the amniotic membrane towards diverse medical applications, help them to sustain. For instance, in May 2024, NovaBay Pharmaceuticals, Inc. introduced an expanded line of Avenova product bundles specifically designed to provide easy, affordable, and effective solutions for dry eye symptoms. Here's the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?